Endocrine Abstracts

Background and aims: liraglutide belongs to glucagon-like peptide-1 receptor agonists (GLP-1 RA) and is widely used for diabetes type 2 (DT2) management as well as for obesity treatment. GLP-1 RA reduce body weight and suppress eating behavior by delaying gastric emptying and affecting arcuate nucleus in hypothalamus. Binge eating disorder (BED) is the most common eating disorder (ED) in individuals with obesity and DT2. BED is characterized by consuming large amounts of food ...

Background and Aims: the war has become a stressful factor for many people in Ukraine. It is known that eating disorders (ED) might be triggered by a great stress. Binge eating disorder (BED) and night eating syndrome (NES) belong to hyperphagic ED mostly affecting those with obesity and diabetes type 2 (DT2). In our study we investigated how the war changed eating behavior and metabolic control in DT2 patients.Materials and Methods: 63 individuals (mean...

Background and aims: Night eating syndrome (NES) is one of the most common eating disorder in patients with obesity and diabetes type 2 (DT2). It may affect the management and outcome of DT2. Liraglutide is used for obesity and DT2 management. It controls glucose metabolism, suppresses hunger, and causes weight loss. Leptin is a hormone produced by adipose tissue after food intake in order to promote satiety and maintain fat storage. Our aim was to evaluate how liraglutide aff...

Background and aims: Diabetes type 2 (DT2) is a chronic condition that damages the whole metabolism. It has a growing incidence and is recognized as epidemic of 21st century. One of the most common complications of DT2 is diabetic nephropathy (DN). It is caused by persistent hyperglycemia and kidney damage. Microalbuminuria is one of the most important hallmarks of DN. Besides, it increases a risk of cardiovascular and neurological complications. Microalbuminuria is defined as...